Cipla Ltd.

NSE: CIPLA BSE: 500087 SECTOR: Pharmaceuticals & Drugs

913.1
-37.45 (-3.94%)
NSE: Today, 03:59 PM

Price Summary

Today's High

₹ 958.5

Today's Low

₹ 909

52 Week High

₹ 997

52 Week Low

₹ 644.25

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.

Company Essentials

Market Cap

73654.52 Cr.

Enterprise Value

73137.51 Cr.

No. of Shares

80.66 Cr.

P/E

29.84

P/B

3.7

Face Value

₹ 2

Div. Yield

0.54%

Book Value (TTM)

₹  247.04

CASH

523.07 Cr.

DEBT

6.06 Cr.

Promoter Holding

36.72%

EPS (TTM)

₹  30.6

Sales Growth

2.3%

ROE

14 %

ROCE

18.08 %

Profit Growth

22.76 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

Dytor Moxicip Novamox Lametec Ibugesic Fourderm CPink CDense Productiv nicotex ActivKids immuno boosters cofsils CIPHANDS OMNIGEL CORYX BRONCOL COUGH SYRUP Cheston

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Ratios

Sales Growth

1 Year2.3%
3 Year5.54%
5 Year4.55%

Profit Growth

1 Year22.76%
3 Year33.47%
5 Year14.44%

ROE%

1 Year14%
3 Year12.55%
5 Year11.66%

ROCE %

1 Year18.08%
3 Year16.27%
5 Year14.59%

Debt/Equity

0.0003

Price to Cash Flow

36.5

Interest Cover Ratio

83.2277392510402

CFO/PAT (5 Yr. Avg.)

1.05253354765703

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2021 36.72 0
Mar 2021 36.73 0
Dec 2020 36.7 0
Sep 2020 36.7 0
Jun 2020 36.68 0
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 33.4716811613045% for the Past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 83.2277392510402.
  • Company has a healthy liquidity position with current ratio of 3.44637668986634.
  • The company has a good cash flow management; CFO/PAT stands at 1.05253354765703.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 7.28817320948896.

 Limitations

  • The company has shown a poor revenue growth of 5.53987584372311% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021
Net Sales 3133.44 3128.02 3807.89 3731.55 3233.12
Total Expenditure 2668.64 2183.28 2676.92 2735.4 2583.42
Operating Profit 464.8 944.74 1130.97 996.15 649.7
Other Income 413.41 45.66 39.17 96.12 49.33
Interest 9.24 14.21 11.69 10.33 8.84
Depreciation 160.42 143.73 140.8 134.57 137.01
Exceptional Items 0 0 0 0 0
Profit Before Tax 708.55 832.46 1017.65 947.37 553.18
Tax 103.98 222.16 272.01 248.44 139.77
Profit After Tax 604.57 610.3 745.64 698.93 413.41
Adjusted EPS (Rs) 7.5 7.57 9.25 8.67 5.13

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Net Sales 11950.69 10768.49 11389.9 12374.01 12659.15
Total Expenditure 9897.26 9172.23 9194.35 9879.69 9991.76
Operating Profit 2053.43 1596.26 2195.55 2494.32 2667.39
Other Income 280.3 129.85 334.88 577.52 913.76
Interest 147.07 39.2 11.9 16.97 36.05
Depreciation 442.69 499.97 529.61 562.04 580.79
Exceptional Items 0 0 -77.52 0 0
Profit Before Tax 1743.97 1186.94 1911.4 2492.83 2964.31
Tax 281.67 212 442.88 604.42 646.14
Net Profit 1462.3 974.94 1468.52 1888.41 2318.17
Adjusted EPS (Rs.) 18.2 12.12 18.24 23.44 28.75

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Equity and Liabilities
Share Capital 160.68 160.9 161.02 161.14 161.25
Total Reserves 11825.2 12639.61 13952.5 15620.77 17241.71
Borrowings 0.13 0.07 0 0 0
Other N/C liabilities 298.57 191.27 202.95 268.82 383.41
Current liabilities 2954.47 2555.83 2731.7 2368.08 2619.29
Total Liabilities 15239.05 15547.68 17048.17 18418.81 20405.66
Assets
Net Block 3826.11 4235.26 4320.03 4127.46 4024.54
Capital WIP 512.81 540.52 435.28 241.32 255.73
Intangible WIP 37.91 15.25 27.32 56.01 64
Investments 3716.59 3648.03 3597.56 3865.46 6481.76
Loans & Advances 551.69 624.98 611.43 583.23 516.63
Other N/C Assets 126.57 138.3 118.38 66.68 35.94
Current Assets 6467.37 6345.34 7938.17 9478.65 9027.06
Total Assets 15239.05 15547.68 17048.17 18418.81 20405.66
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Profit from operations 1743.97 1186.94 1911.4 2492.83 2964.31
Adjustment 473.89 778.6 315.64 187.6 -35.73
Changes in Assets & Liabilities -98.83 573.12 -588 -761 -245.46
Tax Paid -390.63 -331.27 -522.51 -451.38 -664.98
Operating Cash Flow 1728.4 2207.39 1116.53 1468.05 2018.14
Investing Cash Flow -1205.98 -1191.75 -592.72 -1147.71 -1127.18
Financing Cash Flow -547 -1010.8 -350.96 -473.32 -693.89
Net Cash Flow -24.58 4.84 172.85 -152.98 197.07

Corporate Actions

Investors Details

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Promoters 36.68 36.7 36.7 36.73 36.72
kamil hamied 1.36 1.36 1.36 1.36 1.36
mn rajkumar garments llp 0.67 0.67 0.67 0.67 0.67
mustafa khwaja hamied 4.29 4.29 4.29 4.29 4.29
rumana hamied 1.23 1.23 1.23 1.23 1.23
shirin hamied 0.79 0.79 0.79 0.79 0.79
sophie ahmed 5.71 5.71 5.71 5.71 5.71
yusuf khwaja hamied 20.36 20.36 20.37 20.37 20.36
alps remedies private ltd... 0.06 0 0 0 0
samina hamied 2.22 2.22 2.22 2.22 2.22
alps remedies private lim... 0 0.06 0.06 0.06 0.06
okasa pharma private limi... 0 0 0 0.02 0.02
PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Public 23.4 23.48 23.25 22.84 22.21
iepf 0.4 0.4 0.41 0.4 0
nps trust 1.13 1.24 1.41 1.46 0
icici prudential life ins... 1.06 1.28 1.11 1.01 0
PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
FII/DII 39.92 39.82 40.05 40.43 41.07
government pension fund g... 1.68 1.59 1.69 2.33 2.36
hdfc mutual fund 2.4 2.29 1.95 1.69 1.19
icici prudential mutual f... 4.78 3.65 3.04 2.5 1.68
life insurance corporatio... 4.24 2.48 1.73 1.81 2.27
icici prudential mutual f... 4.78 3.65 3.04 2.5 1.68
sbi mutual fund 2.66 2.94 2.96 2.83 3.45
reliance mutual fund 1.09 1.14 0 0 0
aditya birla mutual fund 1.96 1.49 1.13 1.02 0
uti 1.01 0 0 0 0
axis mutual fund 0 1 0 0 0
nippon mutual fund 0 0 1.04 1 0
iepf 0 0 0 0 0.39

Ratings & Research Reports

Company Presentations

Company News

Cipla recalls 7,228 bottles of Solifenacin Succinate tablets26 Jul 2021, 9:57AM Cipla informs about allotment of equity shares under ESOP 17 Jul 2021, 12:31PM Cipla, Dr. Reddy’s, Emcure, Sun Pharma and Torrent to collaborate for clinical trial of Molnupiravir for COVID-19 30 Jun 2021, 1:00PM Cipla gets approval to import Moderna's COVID-19 vaccine in India29 Jun 2021, 5:01PM Cipla informs about schedule of investor meet26 Jun 2021, 3:46PM Cipla informs about analyst meet23 Jun 2021, 11:48AM Cipla gets final approval for Arformoterol Tartrate Inhalation Solution23 Jun 2021, 11:31AM Cipla informs about press release15 Jun 2021, 10:03AM Cipla’s step-down associate company receives complete response letter from USFDA for IV Tramadol 15 Jun 2021, 9:32AM Cipla informs about analyst meet7 Jun 2021, 10:07AM Cipla informs about response to media query1 Jun 2021, 10:06AM Cipla informs about analyst meet26 May 2021, 4:01PM Cipla informs about press release24 May 2021, 9:57AM Cipla informs about press release20 May 2021, 9:48AM Cipla launches RT-PCR test kit ‘ViraGen’ for COVID-19 in India20 May 2021, 9:07AM Cipla informs about earnings call transcript18 May 2021, 5:29PM Cipla reports 68% rise in Q4 consolidated net profit15 May 2021, 9:20AM Cipla signs licensing agreement with Eli Lilly 10 May 2021, 10:47AM Cipla informs about press release10 May 2021, 9:48AM Cipla informs about updates4 May 2021, 11:49AM Cipla’s associate company incorporates wholly-owned subsidiary4 May 2021, 9:25AM Cipla enters into licensing agreement with MSD 28 Apr 2021, 3:43PM Cipla informs about postal ballot notice24 Apr 2021, 2:02PM Cipla doubles Remdesivir production to meet 'unprecedented' demand13 Apr 2021, 4:34PM Cipla enters into agreement to become partner in ABCD Technologies LLP31 Mar 2021, 1:37PM Cipla’s affiliate enters into strategic partnership with SIGA Technologies 23 Mar 2021, 9:15AM Cipla pledges support to ‘Terra Carta’ for sustainable future19 Mar 2021, 9:39AM Cipla informs about analyst meet8 Mar 2021, 12:14PM Cipla voluntarily liquidates wholly-owned step-down subsidiary8 Mar 2021, 10:46AM Cipla informs about liquidation6 Mar 2021, 11:11AM Cipla informs about analyst meet2 Mar 2021, 11:51AM Cipla informs about press release2 Mar 2021, 10:35AM Cipla's arm expands partnership with Alvotech2 Mar 2021, 9:45AM Cipla receives USFDA’s final approval for Sumatriptan Nasal Spray2 Mar 2021, 9:30AM Cipla reports 2-fold jump in Q3 consolidated net profit1 Feb 2021, 11:27AM Cipla recalling over 5.8 lakh packets of gastric ulcer treatment drug in US11 Jan 2021, 9:58AM Cipla informs about disclosure22 Dec 2020, 10:34AM Cipla’s step-down associate company gets regulatory update for intravenous tramadol18 Dec 2020, 1:34PM Cipla informs about press release16 Dec 2020, 10:25AM Cipla enters into partnership with Premier Medical Corporation 16 Dec 2020, 9:13AM Cipla informs about press release18 Nov 2020, 10:31AM Cipla signs licensing agreement with Multi G18 Nov 2020, 9:25AM Cipla looking at sustaining growth through pandemic 9 Nov 2020, 9:26AM Cipla reports 41% rise in Q2 consolidated net profit7 Nov 2020, 10:45AM Cipla launches antibody detection kits for COVID-19 in India29 Oct 2020, 9:12AM Cipla launches generic Nintedanib for treatment of IPF20 Oct 2020, 4:49PM Cipla’s US arm gets complete response letter from USFDA for IV Tramadol 13 Oct 2020, 10:17AM Cipla informs about analyst meeting28 Sep 2020, 4:20PM Cipla gets USFDA’s final approval for Dimethyl Fumarate DR Capsules25 Sep 2020, 9:24AM Cipla informs about allotment of equity shares under ESOP16 Sep 2020, 2:04PM

Cipla Stock Price Analysis and Quick Research Report. Is Cipla an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Cipla and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 2018.14 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Cipla has a Debt to Equity ratio of 0.0003 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Cipla , the EPS growth was 22.6741928739958 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Cipla has OPM of 21.0708459888697 % which is a good sign for profitability.
     
  • ROE: Cipla have a average ROE of 14.0036849099915 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Cipla

X